Oxybutynin (Ditropan), a widely distributed muscarinic antagonist for treating the overactive bladder, has been awaiting a definitive crystal structure for nearly 50 years due to the sample and technique limitations. Past reports used powder X-ray diffraction (PCRD) to shed light on the possible packing of the molecule however a 3D structure remained elusive. Here we used Microcrystal Electron Diffraction (MicroED) to successfully unveil the 3D structure of oxybutynin hydrochloride. We identify several inconsistencies between the reported PXRD analyses and the experimental structure. Using the improved model, molecular docking was applied to investigate the binding mechanism between M muscarinic receptor (MR) and ()-oxybutynin, revealing essential contacts/residues and conformational changes within the protein pocket. A possible universal conformation was proposed for MR antagonists, which is valuable for future drug development and optimization. This study underscores the immense potential of MicroED as a complementary technique for elucidating the unknown pharmaceutical crystal structures, as well as for the protein-drug interactions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11185708 | PMC |
| http://dx.doi.org/10.1101/2024.06.05.597682 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Management of Children and Adolescents with Overactive Bladder Refractory to Treatment with Parasacral Transcutaneous Electrical Nerve Stimulation.
Int Braz J Urol
November 2024
Centro de Distúrbios Urinários Infantis (CEDIMI), Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brasil.
Article Synopsis
- - This study investigated how children aged 4-17 with overactive bladder (OAB) responded to various treatments after not completing sessions of parasacral TENS (pTENS).
- - Out of 30 children, 70% received single treatments, with 57% achieving complete symptom resolution and 28% having partial success, while 30% still faced bothersome symptoms.
- - Results showed that more intensive therapies led to better outcomes, with a significant decrease in Dysfunctional Voiding Scoring System scores and an increase in patient satisfaction reported through Visual Analogue Scale scores.
An Updated Structure of Oxybutynin Hydrochloride.
Adv Sci (Weinh)
October 2024
Department of Biological Chemistry, University of California, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Oxybutynin (Ditropan), a widely distributed muscarinic antagonist for treating the overactive bladder, has been awaiting a definitive crystal structure for ≈50 years due to the sample and technique limitations. Past reports used powder X-ray diffraction (PXRD) to shed light on the possible packing of the molecule however their model showed some inconsistencies when compared with the 2D chemical structure. These are largely attributed to X-ray-induced photoreduction.
View Article and Find Full Text PDFAn Updated Structure of Oxybutynin Hydrochloride.
bioRxiv
June 2024
Department of Biological Chemistry, University of California, Los Angeles, 615 Charles E. Young Drive South, Los Angeles, California 90095, United States.
Oxybutynin (Ditropan), a widely distributed muscarinic antagonist for treating the overactive bladder, has been awaiting a definitive crystal structure for nearly 50 years due to the sample and technique limitations. Past reports used powder X-ray diffraction (PCRD) to shed light on the possible packing of the molecule however a 3D structure remained elusive. Here we used Microcrystal Electron Diffraction (MicroED) to successfully unveil the 3D structure of oxybutynin hydrochloride.
View Article and Find Full Text PDFA muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin.
Acta Neuropathol
March 2024
Department of Pathology, University of California San Diego, La Jolla, CA, USA.
Preclinical studies indicate that diverse muscarinic receptor antagonists, acting via the M sub-type, promote neuritogenesis from sensory neurons in vitro and prevent and/or reverse both structural and functional indices of neuropathy in rodent models of diabetes. We sought to translate this as a potential therapeutic approach against structural and functional indices of diabetic neuropathy using oxybutynin, a muscarinic antagonist approved for clinical use against overactive bladder. Studies were performed using sensory neurons maintained in vitro, rodent models of type 1 or type 2 diabetes and human subjects with type 2 diabetes and confirmed neuropathy.
View Article and Find Full Text PDFRepurposing of US-FDA-approved drugs as negative modulators of ubiquitin specific protease-7 (USP7).
Heliyon
March 2024
Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center of Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan.
Ubiquitin-specific protease7 (USP7) regulates the stability of the p53 tumor suppressor protein and several other proteins critical for tumor cell survival. Aberrant expression of USP7 facilitates human malignancies by altering the activity of proto-oncogenes/proteins, and tumor suppressor genes. Therefore, USP7 is a validated anti-cancer drug target.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!